1Alercht M, Haustein KO. The effectsof β-recptor blocking agents on the microcirculation of health subjects and ofhypertension patients. Int J Clin Pharmacol Ther, 1997, 35: 580
2Zhang Y, Xu k, Han C. Alterations of cardiac β-adrenocetor for subtypes inhypothroid rats. Clin Exper Pharmacol Physiol, 1997, 24: 481
3Kaumann AJ, Preitner F, Sarsero D, et al. CGP12177 causes cardiostimulation andbinds to cardiac putative β4-adrenoceptors in both wild-type and β3-adrenoceptorknockout mice. Mol Pharmacol, 1998, 53: 670
5Lembo G, Iaccarino G, Vecchione C, et al. Insulin enhances endothelial α2-adrenergicvasorelaxation by a pertussis toxin mechanism. Hypertension, 1997, 30: 1128
6Dunn CJ, Lean AP, Wagstaff AJ. Carvedilol, a reappraisal of it pharmacologicalproperties and therapeutic use in cardiovascular disorders. Drugs, 1997, 54(1): 161
7Tomita K, Marumo F. Effect of long term carvedilol therapy on renal function inessential hypertension. J Cardiovasc Pharmacol, 1992, 19(Suppl 1): S97
8Zitta S, Stoschitzky k, Zweiker R, et al. Dynamic renal function testing bycompartmental analysis: assessment of renal functional reserve in essential hypertension.Nephrol Dial Transplant, 2000, 15(8): 1162
9Jacob S, Balletshofer B, Henriksen EJ, et al. Beta-blocking agents in patients withinsulin resistance: effects of vasodilating beta-blockers. Blood Press, 1999, 8(5～6):261
10Fassbinder W, Quarder O. Treatment with carvedilol is associated with asignificant reduction in microalbuminuria: a multicenter randomized study. Int J Pract,1999, 53(7): 519
